Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain

Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain

Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV), an infectious coronavirus first reported in 2012, has a mortality rate greater than 35%. Therapeutic antibodies are key tools for preventing and treating MERS-CoV infection, but to date no such agents have been approved for treatment of...

Full description

Bibliographic Details
Main Authors: Lei He, Wanbo Tai, Jiangfan Li, Yuehong Chen, Yaning Gao, Junfeng Li, Shihui Sun, Yusen Zhou, Lanying Du, Guangyu Zhao
Format: Article
Language:English
Published: MDPI AG 2019-02-01
Series:Viruses
Subjects:
Coronavirus
MERS-CoV
receptor-binding domain
therapeutic antibodies
nanobodies
cross-neutralization
Online Access:https://www.mdpi.com/1999-4915/11/2/166

Similar Items

Similar Items